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Uromodulin is exclusively expressed in the thick ascending
limb and is the most abundant protein secreted in urine
where it is found in high-molecular-weight polymers. Its
biological functions are still elusive, but it is thought to
play a protective role against urinary tract infection, calcium
oxalate crystal formation, and regulation of water and salt
balance in the thick ascending limb. Mutations in uromodulin
are responsible for autosomal-dominant kidney diseases
characterized by defective urine concentrating ability,
hyperuricemia, gout, tubulointerstitial fibrosis, renal cysts,
and chronic kidney disease. Previous in vitro studies found
retention in the endoplasmic reticulum as a common feature
of all uromodulin mutant isoforms. Both in vitro and in vivo
we found that mutant isoforms partially escaped retention
in the endoplasmic reticulum and reached the plasma
membrane where they formed large extracellular aggregates
that have a dominant-negative effect on coexpressed
wild-type protein. Notably, mutant uromodulin excretion
was detected in patients carrying uromodulin mutations.
Thus, our results suggest that mutant uromodulin exerts
a gain-of-function effect that can be exerted by both
intra- and extracellular forms of the protein.
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Uromodulin, also known as Tamm–Horsfall protein, was
discovered in 1950 by Tamm and Horsfall.1 It is a large
glycoprotein ofB105 kDa that is exclusively expressed in the
kidney in the thick ascending limb (TAL) of Henle’s loop.
Uromodulin is a glycosylphosphatidylinositol-anchored
protein mainly localized at the apical plasma membrane
of epithelial tubular cells,2 from which it is released into the
tubular lumen through a proteolytic cleavage by a yet to be
identified protease.3 In the urine, it constitutes the most
abundant protein and it is mainly found as a high-molecular-
weight polymer (Mr 1–10 106).4
Mutations in the UMOD gene encoding uromodulin have
been shown to cause medullary cystic kidney disease type 2
(Online Mendelian Inheritance in Man (OMIM) 603860),
familial juvenile hyperuricemic nephropathy (OMIM
162000),5 and glomerulocystic kidney disease with hyper-
uricemia (OMIM 609886),6,7 collectively referred to as
uromodulin-associated kidney diseases (UAKD). UAKD are
autosomal-dominant disorders characterized by alteration of
urinary concentrating ability and by tubulointerstitial
fibrosis, hyperuricemia, and gout, and in few cases by renal
cysts at the corticomedullary junction.8 Although UAKD are
heterogeneous in terms of age at onset, clinical features, and
presence of cysts, they invariably lead to chronic kidney
disease during the third to fifth decade of life.
To date, 51 mutations have been described. All but three
(in-frame deletions) are missense changes that are clustered
in the N-terminal half of the protein. In vitro studies
performed in diverse cell lines have shown that mutant
uromodulin isoforms are defective in trafficking to the
plasma membrane and are retained in the endoplasmic
reticulum (ER).9–12 Enrichment and aggregation of mutant
uromodulin in the ER have been confirmed in a transgenic
mouse model that we recently reported and in patient
biopsies.10,13 All together, these results suggest ER retention
of mutant uromodulin as a key primary event in UAKD
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pathogenesis. Interestingly, both in vitro and in vivo models
show that mutant uromodulin can in part reach the plasma
membrane carrying mature, post-ER type of glycans.9,10,13
In this study, we investigate the effect of mutant
uromodulin escaping ER quality control. We show that in
both in vitro and in vivo models it forms aggregates at the
plasma membrane and in the tubule lumen. Moreover, we
provide novel evidence supporting that these changes in the
extracellular compartment might be relevant in the human
disease, as we identified mutant uromodulin secretion in
urine samples from UAKD patients. All together, our
data suggest the possibility of an extracellular gain of
function and dominant-negative effect of mutant uro-
modulin isoforms.
RESULTS
Mutant uromodulin is trafficked to and aggregates at the
plasma membrane
We investigated if mutant uromodulin can partially escape
quality control in the ER and is trafficked to the plasma
membrane. To do so, wild-type and mutant (R212C, C256Y,
and C317Y) human uromodulin isoforms were stably
expressed in MDCK (Madin–Darby canine kidney) cells.
The C317Y mutation was previously reported and partially
characterized in vitro.6,14 Uromodulin mutations R212C and
C256Y are novel and were identified after genetic screening in
Italian UAKD families (Figure 1a and b). Similar to previous
studies on uromodulin mutants, all analyzed mutations lead
to partial ER retention of mutant protein (Figure 2a and b).
Interestingly, wild-type protein reaching the plasma mem-
brane assembles into polymeric filaments as described
for urinary protein15 (Figure 3). Although less efficiently,
all mutant isoforms were also trafficked to the plasma
membrane and secreted in the culturing medium. Notably,
mutant protein is unable to assemble into ordered filaments
but rather forms large aggregates on the plasma membrane.
Mutant uromodulin, reaching the plasma membrane and
released by phospholipase C (PLC) digestion, carries mature
post-ER glycosylation, demonstrating that it escaped the ER
quality control and entered the secretory pathway (Supple-
mentary Figure S1 online).
Dominant-negative effect of extracellular mutant
uromodulin on the polymerization of the wild-type isoform
To verify if aggregation of mutant uromodulin isoforms
on the plasma membrane could be detrimental for the
polymerization of the wild-type one, wild-type and mutant
proteins were stably coexpressed in MDCK cells, mimicking
the patient heterozygous state. Equal expression level of the
two isoforms was ensured by using a bicistronic expression
vector. On western blot, coexpression of both isoforms did
not alter the band pattern that was observed when wild type
and mutants were expressed alone and it did not affect the
secretion of the wild type protein (Supplementary Figure S2
online). This shows that despite ER retention of mutant
protein, trafficking of the coexpressed wild-type one is not
altered or at least not to an extent that can be detected in our
experiments. Interestingly, immunofluorescence analysis of
nonpermeabilized cells shows that mutant protein reaching
the plasma membrane colocalizes with the wild-type one in
shortened and less structured polymers when compared with
cells expressing wild-type protein only (Figure 4a). This was
confirmed by the quantification of the average area of
filament clusters (Figure 4b) as well as by differential
migration on sucrose gradient (Figure 5). Indeed, sedimenta-
tion of wild-type protein polymers into higher density
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Figure 1 | Localization of the studied mutations and pedigree charts of the investigated families. (a) Schematic representation of
uromodulin. The three epidermal growth factor (EGF) domains are represented by orange boxes, the D8C domain by a pink box, and the
zona pellucida (ZP) domain (composed of ZP_N and ZP_C subdomains) is represented in blue. The glycosylphosphatidylinositol (GPI)-
anchoring site as well as the glycosylation sites (Y) are shown. Studied mutations are indicated in red. (b) Pedigree charts of the three
families D123, MCKD1, and CM1 bearing uromodulin mutations R212C, C256Y, and C317Y, respectively. *Urine mass spectrometry analysis.
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fractions suggests that they are larger than the ones containing
mutant isoforms also.16 This effect is mediated by co-assembly
of the two isoforms as demonstrated by co-immunoprecipita-
tion of secreted wild-type and mutant uromodulin (Figure 6).
Taken together, these results demonstrate that mutant
uromodulin isoforms that reach the plasma membrane exert
an extracellular dominant-negative effect on wild-type protein
polymerization.
Mutant uromodulin is secreted in the urine of a transgenic
mouse model of UAKD and forms intraluminal casts
We verified whether mutant uromodulin could indeed escape
ER retention and form extracellular aggregates in vivo in a
transgenic (Tg) mouse model of UAKD (TgUmodC147W) that
expresses hemagglutinin (HA)-tagged mutant uromodulin
(C147W),13 corresponding to the patient mutation C148W
that we already characterized in vitro.6,9 As a first evidence of
mutant uromodulin trafficking to the plasma membrane,
we detected its presence in the urine of 12-week-old
TgUmodC147W mice. At this age, secretion of transgenic
uromodulin is similar to the one in expression-matched
mice transgenic for HA-tagged wild-type uromodulin
(TgUmodwt; Figure 7a). Interestingly, urinary mutant uromo-
dulin migrates slightly slower than the wild-type one on
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE). This size difference is eliminated by peptide-
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Figure 2 |Analysis of the trafficking of uromodulin isoforms. (a) Immunofluorescence analysis showing uromodulin in permeabilized
MDCK (Madin–Darby canine kidney) cells stably expressing hemagglutinin (HA)-tagged wild-type (WT) or mutant uromodulin isoforms.
Calnexin is shown as an endoplasmic reticulum (ER) marker. Bar¼ 35 mm. (b) Western blot detection of HA-tagged wild-type uromodulin or
indicated mutants from the medium (M) and the soluble (L) and unsoluble (P) fractions of protein extracts from stably transfected
MDCK cells. Tubulin is shown as a loading control (left panel). Western blot detection of uromodulin present in the cell lysate after
deglycosylation with endoglycosidase H (EndoH; E) or peptide-N-glycosidase F (PNGase F; P); C, untreated sample (right panel).
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Figure 3 | Immunofluorescence showing uromodulin
distribution on the plasma membrane in unpermeabilized
MDCK (Madin–Darby canine kidney) cells stably expressing
hemagglutinin (HA)-tagged wild-type (WT) or mutant
uromodulin isoforms. Wild-type isoform is mainly present as
large polymeric filaments whereas mutant isoforms form
extracellular bulky aggregates. Bar¼ 35 mm.
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N-glycosidase F (PNGase F) digestion, suggesting that the
two isoforms carry different N-glycosylation. Immunofluor-
escence performed on mouse kidney sections confirms the
presence of extracellular mutant uromodulin in the lumen of
TAL tubules. Similar to what is observed in vitro, mutant
protein tends to form aggregates that are never observed in
TgUmodwt mice (Figure 7b and c).
Mutant uromodulin is secreted in the urine of UAKD patients
We assessed the relevance of our in vitro and in vivo obser-
vations by investigating whether secretion of mutant uro-
modulin could also be observed in UAKD patients. We
analyzed the secretion of mutant uromodulin in three
patients bearing different uromodulin mutations (R212C,
C256Y, or C317Y; Figure 1a) and with preserved renal
function (Table 1). Mass spectrometry (MS) analyses show
that in all cases, mutant isoforms are secreted in urine
(Supplementary Figures S3–S5 online). Because summed
peptide intensity can be used as a good proxy for absolute
protein abundance,17 the intensity signals of peptides
specifically assigned to the wild-type protein were compared
with the intensity signals of peptides specifically assigned to
the mutant proteins, whereas signal intensities of common
peptides of both isoforms were not considered. This method
was used to have an estimate of the abundance of the urinary
wild-type and mutant uromodulin isoforms in each patient.
The ratio of the summed intensities of the specific peptides
belonging to each uromodulin form is reported in Table 2.
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Figure 4 |Mutant uromodulin interferes with the polymerization of the wild-type isoform. (a) Immunofluorescence analysis showing
uromodulin on the plasma membrane of unpermeabilized MDCK (Madin–Darby canine kidney) cells stably expressing myc-tagged wild-type
(WT) isoform and either wild-type or mutant hemagglutinin (HA)-tagged isoforms. Staining with anti-HA and anti-myc antibodies is shown.
The presence of the mutant isoform at the plasma membrane interferes with the polymerization of the wild-type one, as polymers look
shortened and more aggregated. Bar¼ 55mm. (b) Quantification of the average surface of uromodulin polymers on the membrane of MDCK
cells coexpressing HA- and myc-tagged uromodulin isoforms. Only polymers containing co-transfected isoforms (positive for both tags)
were quantified (B1000 counts per cell line per experiment, 2 independent experiments). Filaments formed by wild-type and mutant
protein are significantly shortened. **Po0.001.
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The secretion of mutant isoforms R212C, C256Y, and C317Y
was estimated to represent B1.3%, 7.6%, and 35%, respec-
tively, of the wild-type one.
DISCUSSION
To date, 51 mutations in the UMOD gene coding for
uromodulin have been described, all leading to UAKD.
Previous in vitro studies have pointed at ER retention as
a common feature of all investigated mutants.9–12 This was
confirmed in a recently generated UAKD mouse model and
on patient renal biopsy analysis.10,13 All together, these data
led to propose that mutant uromodulin intracellular
aggregation could play a key role in the pathogenesis of the
disease, likely by exerting a gain-of-function effect through
activation of cell stress responses.
In this study, through in vitro and in vivo analyses we
demonstrate that a part of mutant protein can escape the ER
quality control, is trafficked to the plasma membrane, and
secreted. Interestingly, mutant protein tends to form large
extracellular aggregates that interfere with wild-type protein
polymerization, suggesting extracellular gain of toxic func-
tion as an additional consequence of uromodulin mutations.
This effect was clearly evident in in vitro studies that were
carried out in MDCK cells, which, to our knowledge, are the
only cell models able to induce proper uromodulin
polymerization into highly ordered filaments. This allowed
us to show that mutant isoforms are unable to polymerize
but rather form aggregates at the plasma membrane.
Moreover, when wild-type and mutant uromodulin were
coexpressed at equal levels, thereby mimicking the patient
condition, we observed that mutant protein co-assembles
with the wild-type one and exerts a dominant-negative effect
over polymer formation and/or stability. Indeed, the presence
of the mutant protein significantly shortens the polymers, as
demonstrated by their quantification in immunofluorescence
and their differential sedimentation on sucrose gradient. The
dominant-negative effect on protein polymerization suggests
that even if mutant protein has escaped the ER quality
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Figure 5 |Western blot analysis after separation on sucrose
gradient of uromodulin digested by phosphatidylinositol-
specific phospholipase C (PI-PLC) from MDCK (Madin–Darby
canine kidney) cells expressing the myc-tagged wild-type
(WT) isoform and either wild-type or mutant hemagglutinin
(HA)-tagged isoforms. Fraction numbers are indicated from the
top (1 M sucrose, fraction 1) to the bottom (2 M sucrose, fraction 6)
of the gradient. I, input (1/5 of the amount loaded on the
gradient). Uromodulin sediments deeper in the gradient when
wild-type protein is expressed alone.
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Figure 6 |Mutant uromodulin isoforms interact with the wild-type one. (Top panel) Co-immunoprecipitation (co-IP) experiments on
protein from the conditioned medium of MDCK (Madin–Darby canine kidney) cells coexpressing Flag-tagged wild-type (WT) and
hemagglutinin (HA)-tagged uromodulin isoforms. Immunoprecipitation was carried out with an anti-Flag antibody. The presence of co-
immunoprecipitated HA-tagged uromodulin was assessed by western blot analysis. Mutant uromodulin co-assembles with wild-type
protein. (Bottom panel) Same experiment performed on protein from the conditioned medium of MDCK cells expressing HA-tagged wild-
type uromodulin isoform. The absence of co-immunoprecipitated HA-tagged uromodulin in the absence of Flag-tagged isoform
demonstrates the specificity of the assay. *Unspecific signal. IP, immunoprecipitate.
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Figure 7 |Mutant uromodulin is secreted and forms intraluminal casts in a mouse model of UAKD. (a) Transgenic (Tg) hemagglutinin
(HA)-tagged uromodulin secreted in the urine of TgUmodwt and TgUmodC147W mice was analyzed by western blot. The amount of urine loaded
is representative of a 24-h urine collection. Urinary uromodulin was also analyzed after deglycosylation with peptide-N-glycosidase F
(PNGase F). (b) Immunofluorescence performed on kidney sections of TgUmodwt and TgUmodC147W mice showing transgenic uromodulin and
NKCC2 (apical marker of thick ascending limb (TAL) epithelial cells). Uromodulin aggregates are present exclusively in TAL lumen of
TgUmodC147W mice. Bar¼ 50 mm. (c) Immunofluorescence showing at higher magnification uromodulin aggregates present in
TAL lumen of TgUmodC147W mice and absent in TgUmodwt mice. Bar¼ 50mm. C, control nontransgenic animal.
Table 1 | Summary of clinical features in the UAKD patients analyzed
Uromodulin
mutation Patient Sex
Age at urine
collection
Urine-specific
gravity
Urinary creatinine
(mg/dl)
Serum creatinine
(mg/dl)
Serum uric acid
(mg/dl) Gout
Renal
ultrasound
R212C II 1 M 41 1010 65.5 1.08 6.2 No NK
C256Y II 4 M 35 1018 73 1.4 8.9 No NK
C317Y IV 5 M 18 1020 80 0.8 7.5 No NK
Abbreviations: M, male; NK, normal kidney; UAKD, uromodulin-associated kidney diseases.
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control, it is still adopting a nonnative conformation. ER
quality control escape has already been observed for other
disease-causing mutant proteins, for example, alpha-1-
antitrypsin18 and CFTR (cystic fibrosis transmembrane
conductance regulator).19 Interestingly, CFTR folding mutant
DF508 on escape from the ER quality control is altering
cellular lipid trafficking,20 showing that misfolded proteins
that gain access to the distal secretory pathway, in addition of
being nonfunctional, can have a detrimental effect.
In the case of mutant uromodulin, this effect is evident in
not only in vitro models but also in vivo models. Indeed,
immunofluorescence analyses performed on kidney sections
of a mouse model of UAKD (TgUmodC147W mice) show
intraluminal casts containing mutant uromodulin. These
structures are an early finding in the mouse disease that can
be found in virtually all TAL segments at time points (1 and
4 weeks of age) when renal function and nephron integrity
are still preserved (Supplementary Figure S6 online and data
not shown).
We believe that secretion of mutant uromodulin as seen in
MDCK cells and in TgUmodC147W mice is not merely due to
overexpression. The relevance of these findings is indeed
demonstrated by the detection of mutant uromodulin in the
urine of three UAKD patients carrying three different
mutations. Urinary mutant protein is likely derived from
active protein secretion from the plasma membrane and not
because of the presence of cell debris in the urine sample.
Indeed, if that was the case, one would expect mutant
uromodulin to be mainly present as the shorter ER-
glycosylated isoform, which was never detected in western
blots of patient urine. Mutant uromodulin was not found in
the urine of UAKD patients in two earlier studies.21,22 This
discrepancy could be ascribed to the different UMOD
mutations analyzed. However, it should be noticed that in
both previous studies, uromodulin secretion was assessed at
a time point when renal function of UAKD patients was
already severely compromised. In this condition, total uro-
modulin secretion was highly reduced, possibly to such an
extent to hamper the specific detection of mutant protein.
In our experience, this was indeed the case in affected
relatives of the patients analyzed in the current study who
had reduced renal function (data not shown). This suggests
that a mutation-specific effect is unlikely. Rather, mutant
uromodulin secretion (ranging fromB1 to 30% of the wild-
type protein level in our work) is evident in UAKD patients
when renal function is still preserved.
What could be the consequences of extracellular mutant
uromodulin aggregation? It is well known that uromodulin
constitutes the matrix for the formation of hyaline casts.23
Mutant uromodulin with its high propensity to aggregation
could increase the number of hyaline casts formed in the
TAL, leading to tubule obstruction, an event that could
be upstream of inflammation and interstitial fibrosis.
On a more speculative ground, we hypothesize that
aggregation of mutant uromodulin could affect wild-type
protein function by interfering with its polymerization or by
sequestering it in large extracellular aggregates. This could
affect the very recently described role of uromodulin in the
regulation of water/salt balance in the TAL,24 contributing to
urinary concentrating defect and hyperuricemia in UAKD
phenotype.
We believe that our findings have relevance when
considering potential therapeutic strategies for UAKD, in
particular the use of chemical chaperones to rescue mutant
protein retention in the ER. The chemical chaperone sodium
phenylbutyrate was shown to restore mutant uromodulin
trafficking in vitro,25 and the use of this drug has already been
extensively tested for the treatment of other ER-storage
disorders such as alpha-1 antitrypsin deficiency26 or cystic
fibrosis.27 In the case of UAKD, chemical chaperones rescuing
Table 2 | Intensities of specific peptides belonging to wild-type and mutant uromodulin isoforms as detected in urine samples
from UAKD patients and calculation of their relative abundance
Sequence Mass Accession number PEP Intensity sample
The wt/mutant
peptide intensity
%Mutant
vs. wt
Patient II-1 (R212C)
FVGQGGACMAETCVPVLR 1836 IPI99999999 2.843E–3 703,400 76.3 1.3%
FVGQGGAR 790 IPI00013945 9.630E–3 231,460
MAETCVPVLR 1117 IPI00013945 5.089 E–3 53,459,000
Patient II-4 (C256Y)
ACAHWSGHCCLWDASVQVK 2099 IPI00013945 7.90E–11 293,380,000 13.12 7.6%
ACAHWSGHCYLWDASVQVK 2159 IPI99999996 3.85E–08 29,253,000
KACAHWSGHCCLWDASVQVK 2228 IPI00013945 1.03E–14 90,289,000
Patient IV-5 (C317Y)
WHCQCK 803 IPI00013945 0.39716 2,342,100 2.80 35.7%
WHCQCKQDFNITDISLLEHR 2485 IPI00013945 6.92E–08 3,591,500
WHCQYKQDFNITDISLLEHR 2545 IPI99999995 0.036102 2,434,900
SNNGRWHCQCK 1331 IPI00013945 0.011313 281,370
SNNGRWHCQCKQDFNITDISLLEHR 3013 IPI00013945 0.025424 598,510
Abbreviations: Mass, mass of the fragmented peptide; PEP, posterior error probability (probability of a false hit given the peptide identification score and length of peptides);
UAKD, uromodulin-associated kidney diseases; wt, wild type. The mutated amino acid is highlighted in bold.
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intracellular retention would likely increase mutant protein
delivery to the plasma membrane, thereby enhancing
extracellular aggregation. We think that additional work
would be needed to understand the potential negative
consequences of such an effect that would be predicted to
affect the TAL segment and kidney function.
In conclusion, our work shows that mutant uromodulin
isoforms are secreted in the urine of patients with preserved
renal function. Mutant uromodulin seems to have a
higher propensity to aggregation than the wild-type protein
because of either misfolding or different post-translational
modification, for example glycosylation. The formation
of extracellular casts could induce tubule obstruction, cast
formation, and interfere with the function of wild-type
uromodulin and possibly other membrane proteins. Thus,
these data suggest that the proteotoxic effect of mutant
uromodulin isoforms could be exerted through both intra-
and extracellular gain-of-function mechanisms. This should
be taken into account when envisaging therapeutic strategies
for uromodulin-associated renal disorders.
MATERIALS AND METHODS
Uromodulin expression constructs
Wild-type uromodulin tagged with HA (pcDNA_HA_UMOD)
was expressed from pcDNA 3.1(þ ) cloning vector (Invitrogen,
Carlsbad, CA). Missense mutations were introduced in pcDNA_
HA_UMOD by using the Quickchange mutagenesis kit (Stratagene,
La Jolla, CA) following the manufacturer’s instructions. Primers
were designed using the software QuikChange Primer Design
Program. For coexpression experiments, myc- or Flag-tagged and
HA-tagged uromodulin isoforms were stably expressed from
bicistronic vector pVITRO-hygro-mcs under the control of the
elongation factor-1a promoter of mouse and rat, respectively
(Invivogen, San Diego, CA). The HA, myc, or Flag tag was inserted
after the leader peptide, in between T26 and S27 in the protein
sequence as previously described.28
Cell line and culture condition
MDCK cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, 200 U/ml penicillin,
200mg/ml streptomycin, and 2 mmol/l glutamine (complete
medium) at 37 1C, 5% CO2. Stable clones were generated by
transfecting MDCK cells with Lipofectamine 2000 (Invitrogen)
following the manufacturer’s protocol. For pcDNA and pVITRO
constructs, selection was started 24 h after transfection by adding
1 mg/ml G418 (Invitrogen) or 200 mg/ml hygromycin (Invitrogen),
respectively, and was pursued for 2 weeks to obtain a population of
resistant cells.
TgUmod mice and murine urine collection
Generation and characterization of TgUmod mice is described
elsewhere.13 Murine urine was obtained on age- and gender-
matched transgenic and control mice (females, aged 10–12 weeks).
They were housed in light- and temperature-controlled room with
ad libitum access to water and standard chow. The 24-h urine
collections were obtained at baseline in individual metabolic cages.
All animal procedures were carried out at San Raffaele Scientific
Institute (Milan, Italy) according to, and approved by, the San
Raffaele Institutional Animal Care and Use Committee.
Patient and urine collection
Diagnostic criteria for patient collection and UMOD mutational
screening procedures have been previously described.6 Uromodulin
was purified from 20 ml of urine as already reported,3 and
resuspended in distilled water. Purified protein was deglycosylated
with PNGase F (New England Biolabs, Ipswich, MA) in denaturing/
reducing conditions according to the manufacturer’s instructions,
alkylated in 55 mmol/l iodoacetamide or N-ethylmaleimide for
20 min at room temperature, separated on 8% acrylamide
SDS–PAGE, and stained with Coomassie Brilliant Blue (Sigma–
Aldrich, St Louis, MO).
Western blot
MDCK cells were grown to confluence. The complete medium was
replaced with 2 ml of Opti-MEM (Invitrogen). After 24 h, the
conditioned medium was collected, 4 volumes of acetone were
added, and precipitated proteins were resuspended in 100 ml of
phosphate-buffered saline. When indicated, cells were incubated
with phosphatidylinositol-specific-PLC (PI-PLC) digestion medium
(Dulbecco’s modified Eagle’s medium; 20 mmol/l Tris-HCl, pH 7.4;
PI-PLC 0.3 U/ml; Invitrogen) for 3 h in a 5% C02 atmosphere at
37 1C. Cells were lysed in 300ml of octylglucoside lysis buffer
(50 mmol/l Tris-HCl, pH 7.4, 150 mmol/l NaCl, 60 mmol/l octyl-
glucoside, and 1 mmol/l phenylmethylsulfonyl fluoride) for 1 h at
4 1C under rotation. Unsoluble fractions were resuspended in 50 ml
of Laemmli buffer whereas soluble fractions were quantified by the
Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). When indicated,
soluble fractions or PI-PLC digestion medium were deglycosylated
with PNGase F or endoglycosidase H (New England Biolabs). A total
of 30 mg of each protein lysate, 10 ml (1/5) of each unsoluble fraction,
and 20 ml (1/5) of medium-precipitated proteins were loaded onto
reducing 8% SDS–PAGE. Transblotted nitrocellulose membranes
(GE Healthcare, Little Chalfont, Buckinghamshire, UK) were
incubated with mouse monoclonal antibody against HA (1:2000
dilution; Covance Research Products, Princeton, NJ) or myc (1:1000
dilution; Covance), followed by incubation with horseradish
peroxidase-conjugated secondary antibody (1:7500 dilution; GE
Healthcare). Anti-a-tubulin mouse monoclonal antibody (1:1000
dilution; Santa Cruz Biotechnology, Santa Cruz, CA) and polyclonal
anti-transferrin goat antibody (1:1000 dilution; Bethyl Laboratories,
Montgomery, TX) were used as a loading control for lysate and
precipitated medium, respectively. Protein bands were visualized
with the Immobilon Western Chemiluminescent Horseradish
Peroxidase Substrate kit (Millipore, Billerica, MA).
Sucrose gradient
PI-PLC digestion medium was overlaid on a discontinuous gradient
consisting of 1, 1.5, and 2 M sucrose in Dulbecco’s modified Eagle’s
medium and centrifuged at 100,000 g for 2 h. After centrifugation,
the gradient was separated in six fractions that were precipitated
with acetone and analyzed by western blot using a sheep anti-
uromodulin antibody (1:1000 dilution; Abcam, Cambridge, UK).
Immunoprecipitation
MDCK cells grown to confluence (3 dishes 100 mm/line) were
kept for 30 h in Opti-MEM (Invitrogen). The conditioned medium
was collected, pooled, and concentrated on Amicon-Ultra-15 3K
(Millipore) to obtain a total volume of 700 ml. A total of 500ml
of the concentrated medium was added to 40 ml of anti-Flag
M2 affinity gel (Sigma-Aldrich). After an overnight incubation at
4 1C under rotation, the resin was washed three times with 1 ml
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phosphate-buffered saline, resuspended in 60 ml Laemmli buffer, and
boiled. Then, 50ml of the concentrated medium and 30ml of the
immunoprecipitate were loaded on SDS–PAGE and analyzed by
western blot as described above using a rabbit anti-Flag antibody
(1:2000 dilution; Sigma-Aldrich) or a mouse anti-HA antibody
(1:1000 dilution; Covance).
Immunofluorescence
Cells grown on coverslip in 12-well plate were fixed in 4% para-
formaldehyde for 30 min. When needed, cells were permeabilized for
10 min at room temperature with 0.5% Triton X-100. Cells were
labeled for 1 h and 30 min at room temperature with anti-HA (1:500;
Covance) and anti-myc (1:500; Novus Biologicals, Littleton, CO) and
anti-calnexin (dilution 1:500; Sigma–Aldrich) antibodies. After
incubation with the appropriate secondary antibody (1:500; Invitro-
gen), cells were stained with 4,6-diamidino-2-phenylindole and
mounted using FluorSave Reagent (Calbiochem, San Diego, CA).
To collect renal tissue, animals were anesthetized with avertin
and perfused with a 4% paraformaldehyde solution. Kidneys were
taken and fixed in 4% paraformaldehyde solution for additional
16 h and embedded in optimum cutting temperature embedding
medium (Tissue-Tek, Electron Microscopy Sciences, Hatfield,
PA), snap-frozen in a mixture of isopentane and dry ice, and
stored at 80 1C. Immunofluorescence was carried out on tissue
sections (10mm thick) stained with rat anti-HA antibody (Roche,
Indianapolis, IN) and anti-NKCC2 antibody (kind gift from Professor
Sebastian Bachmann, Charite´ University, Berlin, Germany).
All slides were visualized under a DM 5000B fluorescence upright
microscope (Leica DFC480 camera, Leica DFC Twain Software,
40X/0.75 lens; Leica Microsystems, Deerfield, IL) or with an
UltraVIEW ERS spinning disk confocal microscope (UltraVIEW
ERS-Imaging Suite Software, Zeiss 63X/1.4; PerkinElmer Life and
Analytical Sciences Boston, MA). All images were imported in
Photoshop CS (Adobe Systems, Mountain View, CA) and adjusted
for brightness and contrast.
The area of polymers covering the plasma membrane in cells
coexpressing myc-tagged wild-type uromodulin together with either
wild-type or mutant HA-tagged protein was quantified using Image
J software (http://imagej.nih.gov/ij/) (Supplementary Figure S7
online). The analysis was performed on pictures taken at  10
magnification that were adjusted for brightness and contrast and
after setting a threshold to exclude the membrane signal back-
ground. Only polymers positive for both tags were quantified by
setting a selection mask on the HA channel and restoring it on
the myc one. The selected area was quantified by setting an object
size limit of 300 pixels. For each experiment, B1000 objects were
quantified per line. Data are expressed as average±SEM and
compared by unpaired two-tailed t-test analysis (Prism software;
GraphPad, San Diego, CA).
MS analysis
Liquid chromatography–tandem MS (LC–MS/MS) analysis.
Bands of interest were excised from gels of patients, subjected to
reduction by 10 mmol/l dithiothreitol and alkylation by 55 mmol/l
iodoacetamide or N-ethylmaleimide, and finally digested overnight
with trypsin (Roche).29 After acidification, up to 10% formic acid,
peptide mixtures were concentrated and desalted on StageTips mC18
(Proxeon Biosystem, Odense, Denmark)30 and injected in a capillary
chromatographic system (EasyLC, Proxeon Biosystem). Peptide
separations occurred on a RP homemade 15 cm reverse-phase
spraying fused silica capillary column (75 mm i.d. 15 cm), packed
with 3 mm ReproSil-Pur C18-AQ (Dr Maisch GmbH, Ammerbuch-
Entringen, Germany). A gradient of eluents A (H2O with 2% v/v
acetonitrile, 0.5% v/v acetic acid) and B (80% acetonitrile with
0.5% v/v acetic acid) was used to achieve separation, from 7% B (at
0 min, 0.2ml/min flow rate) to 35% B (in 70 min, 0.2 ml/min flow
rate). The LC system was connected to an LTQ-Orbitrap mass
spectrometer (Thermo Fisher Scientific, Waltham, MA) equipped
with a nanoelectrospray ion source (Proxeon Biosystems). MS and
MS/MS spectra were acquired selecting the 10 most intense ions per
survey spectrum acquired in the orbitrap from m/z 300–1750 with
60,000 resolution. Target ions selected for the MS/MS were
fragmented in the ion trap and dynamically excluded for 45 s.
Target value were 1,000,000 for survey scan and 100,000 for MS/MS
scan. For accurate mass measurements, the lock-mass option was
employed.31
Data processing and analysis. For peptide identifications,
Mascot (Matrix Science, version 2.2.07, Boston, MA) search engine
was used. Raw MS files were converted into peaklist (.msm files),
and searched against the database IPI_human_20100628 (86,397
sequences; 35,097,130 residues) supplemented with the on-purpose-
created sequences of human uromodulin variants with mutations
R212C (IPI99999999), C256Y (IPI99999996), and C317Y (IPI99999995).
Enzyme specificity was set to trypsin, allowing a maximum of
two missed cleavages. Cysteine alkylation by iodoacetamide or
N-ethylmaleimide or acrylamide, oxidation of methionine, deami-
dation of asparagines, and protein N-acetylation were all considered
as variable modifications. Mass tolerance was set to 5 p.p.m. and
0.6 Da for precursor and fragment ions, respectively. The criterion
used to evaluate the quality of MS/MS data was a Mascot ion score
cutoff of at least 20.
Data analysis by MaxQuant. To measure the intensity of
peptides, especially the intensity of the mutated peptides and the
correspondent wild-type peptides in each sample from urine of
patients, MS data were analyzed using the MaxQuant software,32,33
version 1.1.1.25, applying the Label-free algorithms.
For MS/MS peak list file construction, up to top 6 peaks per
100 Da window were included for database searching. The generated
peak lists were searched against the concatenated forward
and reverse database IPI_human_20100628 (86,397 sequences;
35,097,130 residues) supplemented with the on-purpose-created
sequences of human uromodulin variants with mutations R212C
(IPI99999999), C256Y (IPI99999996), and C317Y (IPI99999995).
Mass tolerance was set to 7 p.p.m. and 0.6 Th for precursor and
fragment ions, respectively. Cysteine alkylation by iodoacetamide or
N-ethylmaleimide and acrylamide, protein N-terminal acetylation,
asparagine deamidation, and methionine oxidation were set as
variable modifications for the database search. The cutoff false
discovery rate for proteins and peptides was set to 0.01, and peptides
with a minimum of six amino acids were considered for
identification. The derived peptides intensities were used for a
rough estimation of relative peptide abundances.
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SUPPLEMENTARY MATERIAL
Figure S1. Western-blot analysis of HA-tagged uromodulin released
after PLC cleavage from MDCK cell plasma membrane and
deglycosylated with PNGase F or EndoH; control, untreated sample.
Figure S2. Western-blot analysis of uromodulin from MDCK cells
expressing myc-tagged wild-type and either wild-type or mutant
HA-tagged isoforms. Both uromodulin present in the cell lysate
(top row) and secreted in the medium (bottom row) are shown.
Tubulin and transferrin are shown as loading controls.
Figure S3. MS/MS spectra of the wild-type peptide (a) and the
correspondent mutated peptide (b) obtained by analysis of
uromodulin purified from the urine of patient with R212C mutation.
Figure S4. MS/MS spectra of the wild-type peptide (a) and the
correspondent mutated peptide (b) obtained by analysis of
uromodulin purified from the urine of patient with C256Y mutation.
Figure S5. MS/MS spectra of the wild-type peptide (a) and the
correspondent mutated peptide (b) obtained by analysis of
uromodulin purified from the urine of patient with C317Y mutation.
Figure S6. Immunofluorescence performed on kidney sections of
TgUmodwt and TgUmodC147W mice at 1 week of age showing transgenic
HA-tagged uromodulin. Uromodulin aggregates are present
exclusively in TAL lumen of TgUmodC147W mice. Bar¼ 25mm.
Figure S7. Representative pictures for the quantification of polymer
average area on unpermeabilized MDCK cells expressing myc-tagged
wild-type and either wild-type or mutant (C317Y) HA-tagged
uromodulin isoforms. Top row: merged myc (green) and HA (red)
signal. Bottom row: selection outline defining quantified areas.
Bar¼ 100 mm.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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